Andrew S. Goldstein
Plus aucun poste en cours
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Halina Offner | M | - |
Artielle ImmunoTherapeutics, Inc.
 Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 20 ans |
| Arthur A. Vandenbark | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 20 ans |
| Shahab Fatheazam | M | 72 |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 20 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Adolph J. Ferro | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
| Gregory G. Burrows | M | - |
Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 5 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Andrew S. Goldstein
- Réseau Personnel
